This week, I have an announcement to make.

Find out more at
https://LifeScienceTodayPodcast.com


About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. 

Vaccine hesitancy, the most expensive gene therapy in the world, a $178M series D, and a $1.3B buyout

Find out more at
https://LifeScienceTodayPodcast.com

Story References
Sanofi/Takeda
UniQure & CSL
Fog Pharma
Merck + Imago

About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. 

A $145M opioid acquisition, biobucks for the holidays, a series A, and diabetes approvals

Find out more at
https://LifeScienceTodayPodcast.com

Story References
Indivior + Opiant
Regeneron + CytomX
Rezo
Provention

About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.